Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Operations (2019 - 2025)

Cyclerion Therapeutics has reported Cash from Operations over the past 7 years, most recently at 264000.0 for Q3 2025.

  • Quarterly results put Cash from Operations at 264000.0 for Q3 2025, up 84.62% from a year ago — trailing twelve months through Sep 2025 was 1375000.0 (up 77.94% YoY), and the annual figure for FY2024 was 4333000.0, up 79.6%.
  • Cash from Operations for Q3 2025 was 264000.0 at Cyclerion Therapeutics, up from 503000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for CYCN hit a ceiling of 360000.0 in Q4 2024 and a floor of 14455000.0 in Q1 2021.
  • Median Cash from Operations over the past 5 years was 6214000.0 (2023), compared with a mean of 5496894.74.
  • Biggest five-year swings in Cash from Operations: plummeted 96.37% in 2022 and later skyrocketed 123.36% in 2024.
  • Cyclerion Therapeutics' Cash from Operations stood at 8630000.0 in 2021, then increased by 18.39% to 7043000.0 in 2022, then skyrocketed by 78.12% to 1541000.0 in 2023, then skyrocketed by 123.36% to 360000.0 in 2024, then plummeted by 173.33% to 264000.0 in 2025.
  • The last three reported values for Cash from Operations were 264000.0 (Q3 2025), 503000.0 (Q2 2025), and 968000.0 (Q1 2025) per Business Quant data.